PTSM: Pharmaceutical Technology Sourcing and Management, Aug 4, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Aug 4, 2010
Manufacturing
Senior Executives Evaluate Manufacturing Competitiveness
By Patricia Van Arnum
A recently released index based on feedback from more than 400 senior manufacturing executives provides perspectives on the current and future direction in global manufacturing competitiveness.
Supply Chain
Clinical Research Outsourcing in Asia
By Patricia Van Arnum
Increased outsourcing of clinical research in Asia is an important consideration in the pharmaceutical value chain.
Outsourcing
Be Careful for What You Wish
By Jim Miller
Rising labor costs in China may result in increased competition for higher value services.
CSR and Sustainability Forum
A Management Model for Sustainability
By Patricia Van Arnum
The UN Global Compact, a corporate-social-responsibility initiative, releases a management model to help businesses implement sustainability principles.
CEOs Offer Input on Sustainability
By Patricia Van Arnum
A recently released study by Accenture shows that sustainability is becoming an increasingly important part of the strategies and operations of companies.
CSR and Sustainability Forum
A roundup of developments on corporate social responsibility from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here